Encision INC 8-K filings

Encision Inc. announced its decision to voluntarily deregister its common stock and suspend its reporting obligations with the SEC, citing high compliance costs.

Encision, Inc. announces the resignation of CEO and Director Gregory Trudel due to strategic disagreements, appointing long-time board member Robert Fries as Interim CEO.

Encision, Inc. announced the resignation of director Patrick Pace, effective October 30, 2025, citing no disputes with the company.

Encision Inc. announced the completion of a $500,000 private placement and the results of its Annual Meeting of Stockholders, including the election of four directors and approval of executive compensation.

Encision Inc. held its annual meeting on August 15, 2024, electing five directors and ratifying its independent accounting firm.

Encision Inc. announced a net income of $22 thousand for the first quarter of fiscal year 2025, a significant improvement compared to a net loss of $140 thousand in the same quarter of the previous year.

Encision Inc. announced its fourth quarter and full year fiscal 2024 results, showing a decrease in revenue and an increase in net losses compared to the previous year.

Encision, Inc. reports the resignation of director David Newton and the appointment of Robert H. Fries to the board, effective April 17, 2024.

Encision Inc. announced its third quarter fiscal year 2024 results, showing a slight decrease in revenue and a net loss, while navigating a challenging medical device market.